25 Participants Needed

Candesartan for High Blood Pressure in Obesity

(END-RF Trial)

JL
RH
Overseen ByRyan Harris, PhD, CES
Age: 18 - 65
Sex: Any
Trial Phase: Phase < 1
Sponsor: Augusta University

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial will use chemicals and a drug called Candesartan to study how they affect certain receptors related to blood pressure. It focuses on obese individuals who often have high levels of a substance called ET-1, which is linked to high blood pressure. By blocking these receptors, the study aims to see if it can improve their function and help lower blood pressure in obese people. Candesartan has been studied extensively for its effects on blood pressure, particularly in hypertensive and obese patients.

Will I have to stop taking my current medications?

The trial requires that you stop taking medications that affect blood vessel function, like nitrates, and any blood thinners, such as aspirin.

Is Candesartan safe for humans?

Candesartan has been studied for its safety in treating high blood pressure, especially in people with obesity. It may reduce the risk of new-onset diabetes and has been associated with lower all-cause mortality compared to some other treatments, like amlodipine, in obese patients.12345

How does the drug Candesartan differ from other treatments for high blood pressure in obesity?

Candesartan is unique because it blocks the angiotensin II receptor, which helps reduce blood pressure by relaxing blood vessels and decreasing the activity of the renin-angiotensin system, a key factor in obesity-related hypertension. This mechanism also offers potential benefits for improving insulin sensitivity and protecting organs like the heart and kidneys, which are often affected in obese individuals with high blood pressure.15678

What evidence supports the effectiveness of the drug Candesartan for treating high blood pressure in people with obesity?

Research suggests that drugs like Candesartan, which block the renin-angiotensin system, may be beneficial for treating high blood pressure in people with obesity. This is because they can help manage the increased activity of this system, which is often linked to obesity-related high blood pressure and other metabolic issues.1691011

Who Is on the Research Team?

RH

Ryan Harris, PhD

Principal Investigator

Augusta University

Are You a Good Fit for This Trial?

This trial is for adults aged 18-40 who are dealing with high blood pressure and obesity. It's not open to those with cardiovascular, lung, kidney, liver, brain diseases or metabolic disorders; pregnant individuals; people on meds that affect blood vessels or anticoagulants like aspirin; those with anemia, postmenopausal women, or uncontrolled hypertension.

Exclusion Criteria

You are pregnant.
My blood pressure is not controlled, even with treatment.
I have a heart, lung, kidney, liver, brain, or metabolic condition.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Candesartan or placebo for 7 days to assess ETB receptor function

1 week
1 visit (in-person) at baseline, 1 visit (in-person) post-treatment

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Candesartan
  • Placebo
Trial Overview The study is testing the effects of Candesartan (a drug) against a placebo to see if it can improve how well ETB receptors work in obese individuals. This could help understand if these receptors play a role in developing high blood pressure due to obesity.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: CandesartanExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Augusta University

Lead Sponsor

Trials
219
Recruited
85,900+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Published Research Related to This Trial

Obesity is a significant risk factor for hypertension and is often accompanied by issues like insulin resistance and dyslipidemia, which can lead to serious health complications such as left ventricular hypertrophy and increased inflammation.
Antihypertensive medications that target the renin-angiotensin system, like ACE inhibitors and angiotensin receptor blockers, may not only lower blood pressure but also improve metabolic health and protect against organ damage in obese patients.
Is there a rationale for angiotensin blockade in the management of obesity hypertension?Sharma, AM.[2016]

Citations

Is there a rationale for angiotensin blockade in the management of obesity hypertension? [2016]
Diagnosis and management of hypertension in obesity. [2006]
Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. [2022]
Obesity and hypertension. [2019]
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. [2021]
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. [2022]
The treatment of hypertension in obese patients. [2021]
[Hypertension and overweight]. [2021]
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. [2018]
10.United Statespubmed.ncbi.nlm.nih.gov
AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity. [2020]
11.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Pathophysiology and treatment of obesity hypertension. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security